Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b,... INTRODUCTIONRheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by synovitis leading to pain, swelling, stiffness, and progressive disability and destruction of the joints.1 The treatment target for every patient with RA is achieving sustained remission or low disease activity (LDA).2 Many disease‐modifying antirheumatic drugs (DMARDs) are available, including conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs).2 The addition of, or switching to, a b/tsDMARD is recommended for patients with an inadequate response to csDMARDs to optimize therapy to achieve sustained LDA or remission.2–5 Glucocorticoids are efficacious in RA, and short‐term glucocorticoids may be combined with csDMARDs; however, long‐term glucocorticoid treatment is not recommended owing to the risk of long‐term adverse events (AEs) and an increased risk of mortality; thus, glucocorticoid treatment should be tapered and discontinued as soon as possible.1–4Tumor necrosis factor (TNF) plays an essential role in RA pathology.6 Therapies targeting TNF, such as adalimumab, have revolutionized RA treatment over the past two decades.7 Adalimumab is a fully human monoclonal anti‐TNF antibody that has demonstrated efficacy and safety in many clinical trials and has been widely used as a bDMARD for RA treatment since its approval by the US Food and Drug http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arthritis & Rheumatology Wiley

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Download PDF
9 pages

Loading next page...
 
/lp/wiley/efficacy-and-safety-of-abbv-154-for-the-treatment-of-active-rheumatoid-zrGP1shryo

References (19)

Publisher
Wiley
Copyright
© 2025 American College of Rheumatology.
ISSN
2326-5191
eISSN
2326-5205
DOI
10.1002/art.43266
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONRheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by synovitis leading to pain, swelling, stiffness, and progressive disability and destruction of the joints.1 The treatment target for every patient with RA is achieving sustained remission or low disease activity (LDA).2 Many disease‐modifying antirheumatic drugs (DMARDs) are available, including conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs).2 The addition of, or switching to, a b/tsDMARD is recommended for patients with an inadequate response to csDMARDs to optimize therapy to achieve sustained LDA or remission.2–5 Glucocorticoids are efficacious in RA, and short‐term glucocorticoids may be combined with csDMARDs; however, long‐term glucocorticoid treatment is not recommended owing to the risk of long‐term adverse events (AEs) and an increased risk of mortality; thus, glucocorticoid treatment should be tapered and discontinued as soon as possible.1–4Tumor necrosis factor (TNF) plays an essential role in RA pathology.6 Therapies targeting TNF, such as adalimumab, have revolutionized RA treatment over the past two decades.7 Adalimumab is a fully human monoclonal anti‐TNF antibody that has demonstrated efficacy and safety in many clinical trials and has been widely used as a bDMARD for RA treatment since its approval by the US Food and Drug

Journal

Arthritis & Rheumatology – Wiley

Published: Jun 10, 2025

There are no references for this article.